3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Blade Therapeutics, Inc. is a company with 3 orphan drug designations across 2 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| idiopathic pulmonary fibrosis | Sodium-3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoateN-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide | Des.TrialAppr. |
| systemic sclerosis | cudetaxestat | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio